Zicam receives REX award:
biz.yahoo.com
ZICAM(TM) Cold Remedy Wins Retail Excellence (REX) Award
WOODLAND HILLS, Calif., Oct. 30 /PRNewswire/ -- Gel Tech LLC, a joint venture between Gum Tech International, Inc., (Nasdaq: GUMM - news) and BioDelivery Technologies, Inc., today announced that Zicam(TM) Cold Remedy was awarded a 2000 Retail Excellence (REX) Award by Drug Store News.
Based on voting by key buying and merchandising executives representing the $88-billion drug chain industry, Drug Store News annually presents REX awards to those products and companies that have distinguished themselves in terms of financial performance, innovation and overall excellence in their respective categories.
``To win the REX Award was very exciting considering that Zicam(TM) was in competition with products distributed by major multi-national consumer product companies,'' said Jim Marini, Gel Tech National Sales Manager. ``This award is particularly gratifying because it is determined by people within the retail industry who recognize the sales impact Zicam(TM) has had in our OTC category.''
The awards are a reflection of the company or product's outstanding performance as seen through the eyes of influentials within the retail drug chain industry. Christopher Conboy Jr., Publisher of Drug Store News, commented: ``These awards are particularly significant because of the vast number of excellent products that must compete for attention in the retailing field.'' Drug Store News has acted as the official host of the REX Awards event for the past 16 years.
Added Marie Griffin, Drug Store News Associate Publisher/Editor-in-Chief, ``REX winners are not simply those products that sold with high velocity. REX winners contributed something extra to the category, whether it was originality, an upgrade over pre-existing products, or a particularly effective promotional program. Those companies that won REX Awards are seen by retailers -- drug chains, mass merchandise chains or food/drug combination chains -- as their most effective partners in growing the business.''
Zicam(TM) Cold Remedy was specifically designed to significantly reduce the duration and severity of the common cold, including nasal congestion, sneezing, and coughing. Colds are generally caused when viruses bind with the ICAM-1 receptor sites on cells lining the nasal cavity. Scientists hypothesize that ionic zinc may fill grooves or canyons on the cold-causing viruses, inhibiting or blocking the virus's ability to bind to the receptor sites. Zicam(TM) Cold Remedy uses a proprietary gel matrix to apply an emulsification of ionic zinc, known as Zinullose(TM), directly to the nasal cavity.
Zicam(TM) is developed by Gel Tech, LLC, a joint venture between Gum Tech International, Inc., a publicly held company located in Phoenix, AZ and BioDelivery Technologies, Inc., a privately held biotechnology company. Gum Tech and BDT are engaged in the development of unique delivery systems for delivering bioactive compounds.
Zicam(TM) Cold Remedy is current available at more than 50,000 drug stores, grocery stores, pharmacies, mass merchants, club stores and convenience stores nationwide. For more information, call 1-877-942-2626 or log onto www.zicam.com.
Forward Looking Statement Disclaimer:
This news release contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995, including statements regarding the hypothesis that ionic zinc may reduce the severity of the common cold. These forward-looking statements are based on the Company's expectations and are subject to a number of risks and uncertainties, many of which cannot be predicted or quantified and are beyond the Company's control. Future events and actual results could differ materially from those set forth in, contemplated by, or underlying the forward-looking statements. Factors that could cause actual results to differ materially from the Company's expectations include ongoing clinical research with no guarantee that ionic zinc works as hypothesized. |
